Adjuvant Chemotherapy Not as Effective Against Smaller Tumors in Triple-Negative Breast Cancer

By Keightley Amen - Last Updated: June 4, 2022

Triple-negative breast cancer (TNBC) teds to have relatively poor long-term outcomes compared to other subtypes of breast cancer. A study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting examined outcomes with adjuvant chemotherapy in stage I TNBC according to tumor size.

Researchers mined the ICES database to locate records of 610 patients diagnosed with stage I TNBC from 2012 to 2014. They found 610 such patients, then compared differences in overall survival (OS) between groups, based on tumor size.

Of the total population, 183 had a tumor size of 1 cm or smaller, and 427 had a tumor size more than 1 cm up to 2 cm. Analysis showed that patients with smaller tumor size who received adjuvant chemotherapy did not have a significant difference in OS compared to those who did not receive adjuvant chemotherapy. But in the group of patients with larger tumors, those who received adjuvant chemotherapy had significantly better OS than the patients who did not.

The authors, led by Kathryn Shum of the Schulich School of Medicine and Dentistry at Western University in Ontario, Canada, concluded that patients with larger TNBC tumors should receive adjuvant chemotherapy for better OS, but that clinicians should be aware that this treatment strategy in patients with smaller tumors may be overtreatment.

Post Tags:ASCO 2022 Annual MeetingASCO 2022 Breast Cancer News